english.prescrire.org > Prescrire International > N°134 - January 2013

n°134

January 2013

Issue Contents
Editorial

Free  Clinical research: access to raw data is necessary

p.4
Regulators and industry have to deliver

New Products


Roflumilast (New Drug)

p.5-9
Doubtful efficacy in COPD but clear harms

Phosphodiesterase inhibitors. Various uses

p.7

Oxycodone + naloxone (New Combination)

p.10-11
Choose morphine and optimal laxative therapy instead

INN common stem: -stat

p.11

Botulinum toxin type A and neurogenic urinary incontinence (New Indication)

p.12-13
Sometimes beneficial, if used safely

Adverse Effects


Prevention of wrong-site and wrong-patient surgical errors

p.14-16
Routine checking and patient empowerment

Dental X-rays: meningiomas?

p.16
Potential harm of diagnostic tests

Free  Azithromycin: cardiovascular deaths

p.17
Beware risk factors for QT prolongation

Free  Saxagliptin and tuberculosis

p.17
Immunosuppressive effects

Free  Corticosteroid injections: serious infections and necrosis

p.17
Do not endanger patients

Limiting the adverse effects of androgen suppression

p.21

Prescrire's advice

p.22
Choice of treatment for locally advanced prostate cancer

Reviews


Locally advanced prostate cancer

p.18-23
Effective treatments, but many adverse effects

Type 2 diabetes: increased mortality with low HbA1c

p.23
HbA1c between 7 and 7.5 is fine

Outlook


Direct-to-consumer advertising of prescription drugs: European Commission persists in putting industry's interests first

p.24-27

How to provide the public with relevant health information: 10 concrete proposals

p.26

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe